Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.29

Mkt cap

11M

Volume

136K

High

3.57

P/E Ratio

-0.01

52-wk high

152.40

Low

3.29

Div yield

N/A

52-wk low

1.80

Cingulate reported a Q2 2024 GAAP EPS of $(5.47), which is significantly lower than the estimated $(0.47).

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:47 am

Trading halt status for Cingulate Inc. (CING) was updated at 8:55:00 AM ET. The halt was due to pending news, and trading is expected to resume shortly.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 12:55 pm

Trading for Cingulate Inc. (CING) was halted at 7:50:00 p.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:50 pm

Cingulate has been granted European Patent Number EP3261625 for its 'Tripulse Release Stimulant Formulations' aimed at treating Attention Deficit/Hyperactivity Disorder (ADHD). This patent could enhance Cingulate's market position and intellectual property portfolio.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 5:09 pm

Cingulate shares are trading lower following the company's announcement of the exercise of warrants, resulting in $1.86 million of gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:29 pm

Cingulate Inc. (NASDAQ:CING) announced the exercise of Series A and B warrants, generating $1.86M in gross proceeds. The exercise price was reduced to $0.585 per share. New Series C and D warrants will be issued, with different expiration dates.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 1:16 pm

Cingulate has completed twelve required registration batches for its ADHD drug CTx-1301, marking a significant milestone in its development. The company is now preparing a New Drug Application for submission to the FDA for marketing clearance.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:22 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Sharps Technology (STSS) saw the highest gain with a 56.5% increase, while TransCode Therapeutics (RNAZ) experienced the largest decline, falling by 13.2%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 8:31 pm

In Wednesday's pre-market session, several health care stocks experienced significant movements. Mustang Bio (MBIO) saw a 51.6% increase, while NeuroBo Pharmaceuticals (NRBO) rose by 30.78%. Rezolute (RZLT) and Akso Health Group (AHG) also saw gains of 25.0% and 16.26%, respectively. On the losing side, LifeStance Health Group (LFST) declined by 18.6%, and Lipella Pharmaceuticals (LIPO) fell by 11.84%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 12:06 pm

In Tuesday's after-market session, several health care stocks experienced significant movements. Rezolute (RZLT) saw a 52.7% increase, Mustang Bio (MBIO) rose by 30.64%, and Qilian Intl Hldg Gr (QLI) increased by 14.77%. On the downside, Durect (DRRX) fell by 13.2%, Cingulate (CING) decreased by 10.1%, and Haemonetics (HAE) dropped by 8.79%.

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.